Singulex, Inc., In Partnership With Tecan, Commences Commercial Development Of Ultrasensitive Sgx Clarity™ System For In Vitro Diagnostics Market

ALAMEDA, Calif.--(BUSINESS WIRE)--Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery, today announced an agreement to co-develop the Sgx Clarity™ system with Tecan, a leading global provider of laboratory automation instruments. The partnership will incorporate Singulex’s SMC technology and customized consumables onto Tecan’s Freedom EVO® liquid handling platform. By integrating Singulex’s proprietary ultrasensitive detection technology with Tecan’s existing platform, Singulex expects to be able to commercialize the ultrasensitive immunoassay system for the in vitro diagnostics (IVD) market as early as 2016.

Help employers find you! Check out all the jobs and post your resume.